These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 29803629)

  • 1. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
    Abdallah CG; Sanacora G; Duman RS; Krystal JH
    Pharmacol Ther; 2018 Oct; 190():148-158. PubMed ID: 29803629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function.
    Duman RS; Shinohara R; Fogaça MV; Hare B
    Mol Psychiatry; 2019 Dec; 24(12):1816-1832. PubMed ID: 30894661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug.
    Pałucha-Poniewiera A
    Pharmacol Rep; 2018 Oct; 70(5):837-846. PubMed ID: 30086517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cortical functional hyperconnectivity in a mouse model of depression and selective network effects of ketamine.
    McGirr A; LeDue J; Chan AW; Xie Y; Murphy TH
    Brain; 2017 Aug; 140(8):2210-2225. PubMed ID: 28899017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.
    Pešić V; Petrović J; M Jukić M
    Drug Dev Res; 2016 Nov; 77(7):414-422. PubMed ID: 27546787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.
    Krystal JH; Kaye AP; Jefferson S; Girgenti MJ; Wilkinson ST; Sanacora G; Esterlis I
    Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2305772120. PubMed ID: 38011560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections.
    Duman RS
    Depress Anxiety; 2014 Apr; 31(4):291-6. PubMed ID: 24616149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
    Abdallah CG; Sanacora G; Duman RS; Krystal JH
    Annu Rev Med; 2015; 66():509-23. PubMed ID: 25341010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
    Krystal JH; Sanacora G; Duman RS
    Biol Psychiatry; 2013 Jun; 73(12):1133-41. PubMed ID: 23726151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence.
    Averill LA; Fouda S; Murrough JW; Abdallah CG
    Adv Pharmacol; 2020; 89():163-194. PubMed ID: 32616206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine and the Future of Rapid-Acting Antidepressants.
    Riggs LM; Gould TD
    Annu Rev Clin Psychol; 2021 May; 17():207-231. PubMed ID: 33561364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.
    Gould TD; Zarate CA; Thompson SM
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():213-236. PubMed ID: 30296896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synaptic mechanisms underlying rapid antidepressant action of ketamine.
    Kavalali ET; Monteggia LM
    Am J Psychiatry; 2012 Nov; 169(11):1150-6. PubMed ID: 23534055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect.
    Cui W; Ning Y; Hong W; Wang J; Liu Z; Li MD
    Mol Neurobiol; 2019 May; 56(5):3484-3500. PubMed ID: 30140973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.
    Abdallah CG; Averill LA; Krystal JH
    Ann N Y Acad Sci; 2015 May; 1344(1):66-77. PubMed ID: 25727103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
    Pham TH; Gardier AM
    Pharmacol Ther; 2019 Jul; 199():58-90. PubMed ID: 30851296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine.
    Miller OH; Yang L; Wang CC; Hargroder EA; Zhang Y; Delpire E; Hall BJ
    Elife; 2014 Oct; 3():e03581. PubMed ID: 25340958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research.
    Lv S; Yao K; Zhang Y; Zhu S
    Neuropharmacology; 2023 Mar; 225():109378. PubMed ID: 36539011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine as a fast acting antidepressant: current knowledge and open questions.
    Salvadore G; Singh JB
    CNS Neurosci Ther; 2013 Jun; 19(6):428-36. PubMed ID: 23578128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.